Myriad Genetics Inc (MYGN)

Debt-to-equity ratio

		Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Long-term debt	US$ in thousands	38,800	38,700	38,500	38,500	38,400	—	0	—	—	—	0	0	0	—	—	224,400	225,200	225,100	225,000	233,500
Total stockholders’ equity	US$ in thousands	740,500	760,000	783,200	683,400	735,200	835,200	885,800	916,600	947,400	950,100	967,800	968,600	902,500	875,200	909,300	918,200	967,200	1,077,200	1,074,500	1,088,900
Debt-to-equity ratio		0.05	0.05	0.05	0.06	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.24	0.23	0.21	0.21	0.21

June 30, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $38,800K ÷ $740,500K
= 0.05

The debt-to-equity ratio of Myriad Genetics Inc has remained consistently low over the past six quarters, ranging between 0.00 to 0.06. This suggests that the company relies more on equity financing rather than debt to fund its operations and expansion. The significant decrease in the ratio from 0.24 in September 2020 to 0.00 in March 2023 indicates a reduction in the company's debt levels relative to its equity. Overall, the stability and low level of the debt-to-equity ratio indicate a conservative financial strategy, providing the company with a strong financial position and lower financial risk.